Company intelligence / Profile preview

Yichang Tianren Pharmaceutical

Yichang, Hubei, China

Ownership: Private
Development stage: Other

Overview

Manufactures and supplies chemical APIs and intermediates including valacyclovir hydrochloride, tadalafil, and abidor hydrochloride (the latter recognized for antiviral effect including against COVID-19 and influenza). Abidor hydrochloride was officially approved in China in March 2020 and has become a significant product during the pandemic[1].

Therapeutic areas: Men's HealthInfectious Diseases
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Yichang Tianren Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yichang Tianren Pharmaceutical.

Explore the full profile